Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer

Inclusion Criteria

• •A diagnosis of breast cancer with evidence of 1) unresectable, locally recurrent, or 2) metastatic disease.
• •HER2 positive disease (3+ by immunohistochemistry \[IHC\] or FISH-positive)
• •Candidate for treatment with trastuzumab. Prior treatment with trastuzumab and or/ lapatinib in the neoadjuvant, adjuvant or metastatic disease setting is permitted. Treatment with hormone therapy in the adjuvant and/or advanced disease setting is permitted.